TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35333880
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg moxidectin
Study: 35333880
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg moxidectin
Study: 35295203
Drug: TCM oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCM oral therapy combined with medicinal bath
Study: 35295203
Drug: TCM oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCM oral therapy
Study: 36079817
Drug: Potassium nitrate
Normalized name: Potassium Nitrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium nitrate (10 mmol, 625 mg of nitrate)
Study: 35932889
Drug: Immediate telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate telephone smoking cessation support (TSI) for 6 weeks with pharmacotherapy
Study: 39441642
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (iCBT)
Study: 36243929
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (50000 IU cholecalciferol weekly for three months)
Study: 35476115
Drug: Ibuprofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (10 mg/kg child weight)
Study: 34112100
Drug: Topical testosterone
Normalized name: testosterone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical testosterone
Study: 35231008
Drug: Topical estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estrogen
Study: 36085409
Drug: Sub-marginal instrumentation
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-marginal instrumentation before surgical treatment
Study: 34246761
Drug: Full-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-treatment group (8 weeks of binocular treatment using therapeutic software application in virtual reality headset)
Study: 34246761
Drug: Sham-crossover group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-crossover group (4 weeks of sham treatment followed by 4 weeks of binocular treatment)
Study: 34246761
Drug: Full-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-treatment group
Study: 35956935
Drug: NanoBEO (essential
Approvals — FDA: no, EMA: no, PMDA: no
Description: NanoBEO (essential oil of bergamot) administered as a single therapeutic dose via an airless dispenser.
Study: 34785535
Drug: No fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No fenofibrate therapy
Study: 32404062
Drug: Probiotics administered
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics administered twice daily during antibiotic treatment for up to 1 week after completion of antibiotics
Study: 35121932
Drug: Flt3 ligand
Normalized name: Allogeneic natural killer (NK) cells derived from CD34+ human placental stem/progenitor cells. The cells are expanded and differentiated in the presence of cytokines including thrombopoietin, SCF, Flt3 ligand, IL-7, IL-15 and IL-2 to generate the NK cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flt3 ligand (CDX-301) pre-treatment with anti-DEC-205-NY-ESO-1 vaccine
Study: 35121932
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anti-DEC-205-NY-ESO-1 vaccine without Flt3 ligand)
Study: 34032900
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein intake (> 2.1 g protein/kg lean body mass/day)
Study: 34032900
Drug: Recommended protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended protein intake (1.1 g protein/kg lean body mass/day)
Study: 34067261
Drug: Cobalt‐chrome‐based metal‐ceramic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobalt‐chrome‐based metal‐ceramic prostheses using CAD/CAM (CC‐MC)
Study: 34067261
Drug: Zirconia‐based ceramic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zirconia‐based ceramic prostheses using CAD/CAM (CC‐Zr)
Study: 34067261
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (MC, CC‐MC, CC‐Zr)
Study: 35316121
Drug: treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment-as-usual (TAU) group
Study: 32529966
Drug: Psychedelic-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychedelic-assisted therapy (psilocybin, LSD, ayahuasca, MDMA)
Study: 36100930
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (HBOT) - 90 min at 203 kPa daily for 20 days
Study: 35731065
Drug: Selected physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selected physical therapy program only (Control group)
Study: 34480773
Drug: Five-session online
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-session online imaginal exposure therapy (n=65)
Study: 34570916
Drug: Semaglutide 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 0.4 mg once-daily subcutaneous
Study: 35306553
Drug: Mesalazine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine treatment
Study: 35212023
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral estradiol
Study: 33765420
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (phenprocoumon, acenocoumarol, or warfarin; target INR 2.0-3.0) for 90 days
Study: 35656931
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist
Study: 35394123
Drug: 250-mg azithromycin
Normalized name: azithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250-mg azithromycin test formulation
Study: 35394123
Drug: 250-mg azithromycin
Normalized name: azithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250-mg azithromycin reference formulation
Study: 34819147
Drug: Low-dose calcium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose calcium supplementation (500 mg elemental calcium/day)
Study: 34819147
Drug: Standard high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard high-dose calcium supplementation (1500 mg elemental calcium/day)
Study: 33709626
Drug: ModraDoc006/r 30-20/100-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ModraDoc006/r 30-20/100-100 (30 mg once weekly with ritonavir 100 mg in the morning, and 20 mg with ritonavir 100 mg in the evening)
Study: 32212800
Drug: m-DCF regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-DCF regimen (docetaxel 40 mg/m2, cisplatin 40 mg/m2, 5-fluorouracil 400 mg/m2)
Study: 32212800
Drug: EOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOX regimen (epirubicin 50 mg/m2, oxaliplatin 130 mg/m2, capecitabine 625 mg/m2)
Study: 34583675
Drug: CRP ≤
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP ≤ 22 mg/L combined with rhinorrhea
Study: 34583675
Drug: PCT ≤
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCT ≤ 0.18 ng/mL combined with rhinorrhea
Study: 34583675
Drug: CRP ≤
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP ≤ 22 mg/L and PCT ≤ 0.18 ng/mL combined with rhinorrhea
Study: 35288387
Drug: Current intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current intravenous fluid care
Study: 35933415
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) 150 mg oil twice daily (300 mg daily) for 8 days before chemotherapy
Study: 34147245
Drug: Neuromuscular block
Normalized name: Neuromuscular blocking agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular block using rocuronium (mean dose 12.7 mg, 0.7 mg kg−1)
Study: 34826148
Drug: Oral fexofenadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fexofenadine combined with topical treatment (topical tacrolimus 0.03–0.1% ointment once daily, topical fluticasone propionate 0.05% cream once daily, paraffin‐based emollients) for 8 weeks
Study: 34826148
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment only (topical tacrolimus 0.03–0.1% ointment once daily, topical fluticasone propionate 0.05% cream once daily, paraffin‐based emollients) for 8 weeks
Study: 34203924
Drug: Therapies with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies with transference interpretations
Study: 34203924
Drug: Therapies without
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies without transference interpretations
Study: 32988624
Drug: Olaparib (300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300mg oral tablets, twice daily for 28 days)
Study: 35692186
Drug: THC (13-49
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (13-49 mg)
Study: 35896910
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy plus usual care (RTUC)
Study: 35314257
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg or 25 mg)
Study: 36198292
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TRE and HIIT (TREHIIT)
Study: 34776146
Drug: Multicomponent exercise
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent exercise program (MCEP) performed twice weekly for two months
Study: 32852574
Drug: Duloxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (40 mg BID) + innovative pelvic floor muscle training (iPFMT)
Study: 34050197
Drug: Dose 1
Normalized name: Aldose 1-epimerase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 Curry (D1C) - 6g mixed spices
Study: 34050197
Drug: Dose 2
Normalized name: Fluzone High-Dose 2011-2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 2 Curry (D2C) - 12g mixed spices
Study: 34050197
Drug: Dose 0
Normalized name: Femhrt Low Dose 0.5/2.5 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 0 Control (D0C) - low-polyphenol, no spices
Study: 36242060
Drug: Whole brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole brain radiation therapy for synchronous brain metastases with irradiation protecting the hippocampus
Study: 36242060
Drug: Whole brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole brain radiotherapy for sequential brain metastases to boost irradiation
Study: 32900266
Drug: Acute ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute ketamine dosing
Study: 32900266
Drug: Maintenance ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance ketamine therapy (1 mg/kg, once or twice weekly for 3 months)
Study: 37943580
Drug: Supervised therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised therapy
Study: 35522253
Drug: Physical Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Activity Group (PAG) - two weekly group exercise sessions and two to three home-based exercise sessions per week
Study: 33295128
Drug: Bilateral erector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral erector spinae plane block using 20 mL bupivacaine 0.25% at the level of the T7 transverse process
Study: 33295128
Drug: Bilateral sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral sham block using 20 mL normal saline
Study: 32410819
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of 150 mg of econazole with 6 mg of benzydamine
Study: 32410819
Drug: Econazole single-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Econazole single-drug formulation
Study: 32410819
Drug: Benzydamine single-drug
Normalized name: benzydamine
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine single-drug formulation
Study: 34293615
Drug: FFC group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFC group: tap water containing FFC (0.15g/L) given daily for 5 days
Study: 34293615
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: normal drinking water and feed given daily
Study: 36186931
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Crocus sativus capsules twice daily
Study: 34427941
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tapentadol
Study: 33979487
Drug: Medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical management (episodic antimicrobial treatment)
Study: 32250190
Drug: Topical olopatadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical olopatadine hydrochloride 0.1%
Study: 35109889
Drug: Kangxianhuanji granule,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangxianhuanji granule, 10 g each time, two times daily for 4 weeks
Study: 35109889
Drug: Placebo granule,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo granule, 10 g each time, two times daily for 4 weeks
Study: 34552099
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus ATR inhibitor (berzosertib)
Study: 35419986
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (rhTNFR:Fc PFS and LYO)
Study: 33418457
Drug: SPN-812 (viloxazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-812 (viloxazine extended-release) 100-600 mg/day
Study: 35094667
Drug: 6 mg·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg·kg‐1 caffeine + 10% maltodextrin (CHO+CAFMR)
Study: 35094667
Drug: 6 mg·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg·kg‐1 caffeine (CAFMR)
Study: 34938848
Drug: Take Care
Normalized name: ALCOHOL 62 mL in 100 mL TOPICAL SPRAY [Take Care Clinic Instant Hand Sanitizer Spray]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Care of Me program (8-week online integrated treatment with 12 modules)
Study: 35830497
Drug: Fitbit in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitbit in combination with behaviour change strategies (FB+)
Study: 32135143
Drug: Expedited partner
Normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expedited partner therapy awareness
Study: 32135143
Drug: Expedited partner
Normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expedited partner therapy prescription receipt
Study: 32135143
Drug: Willingness to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willingness to dispense expedited partner therapy prescriptions
Study: 32135143
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of azithromycin for chlamydia treatment
Study: 32135143
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of cefixime for gonorrhea treatment
Study: 33644992
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection (RCI) 80 units twice weekly for 12 weeks, followed by either RCI or placebo for another 12 weeks.
Study: 32493448
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin A supplementation
Study: 32289741
Drug: Gliclazide 60
Normalized name: Gliclazide 60 mg prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide 60 mg
Study: 33287271
Drug: L-band PALSAR-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-band PALSAR-2
Study: 33060436
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3, 2000 IU/day for 6 months
Study: 34083338
Drug: Relating Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relating Therapy (RT) plus Treatment as Usual (TAU)
Study: 32981536
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg slow-release)
Study: 35960649
Drug: Systemic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic administration of lidocaine (SA, lidocaine 1%)
Study: 33487259
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 300,000 IU vitamin D3
Study: 32064725
Drug: CIN-Zn (756.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIN-Zn (756.6 μmol/L cinnamaldehyde and 70 μmol/L zinc)
Study: 32064725
Drug: CIT (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIT (1.6 mmol/L citral)
Study: 32064725
Drug: CIT-ISO (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIT-ISO (1.6 mmol/L citral and 1.3 mmol/L isopulegol)
Study: 33124098
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional treatment)
Study: 35605426
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol (20 mg; 40 mg; 80 mg; 80 mg; and 80 mg)
Study: 35605426
Drug: Intravenous hydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydralazine (10 mg, up to 5 doses)
Study: 33709237
Drug: High suspension
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High suspension and low incision (HSLI) surgery
Study: 39117415
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses
Study: 36302125
Drug: ABI-H2158 (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-H2158 (100, 300, or 500 mg QD or 300 mg BID)
Study: 36302125
Drug: ABI-H2158 (5-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-H2158 (5-500 mg single ascending dose)
Study: 36302125
Drug: ABI-H2158 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-H2158 (300 mg QD or BID for 10 days)
Study: 36302125
Drug: ABI-H2158 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-H2158 (300 mg QD for 14 days)
Study: 37153876
Drug: Daratumumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab monotherapy
Study: 35387759
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg Ursodeoxycholic acid (UDCA) for 6 months
Study: 34224554
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran with reduced particle size (WB RPS), 20 g daily for 1 month
Study: 34674667
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium bicarbonate tablets titrated up to a maximum of 3 g bd (6 g total) for 12 weeks
Study: 34740020
Drug: HCV communication
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV communication with alters currently enrolled in drug treatment
Study: 34740020
Drug: HCV communication
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV communication with alters sharing drug preparation equipment
Study: 34740020
Drug: HCV communication
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV communication with alters with daily/weekly interactions
Study: 33256626
Drug: Trial Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial Sequential Analysis
Study: 39023253
Drug: Abemaciclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib plus endocrine therapy
Study: 38723189
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol
Study: 38723189
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist protocol
Study: 33639116
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (CPTG)
Study: 36053841
Drug: Narcotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narcotic medication
Study: 32930952
Drug: Deferasirox (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (20 mg/kg)
Study: 36575425
Drug: Exposure-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based therapy
Study: 34556006
Drug: Emotion-focused group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotion-focused group therapy (EFGT)
Study: 32346962
Drug: Oral Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tranexamic Acid (TXA) 250 mg twice daily
Study: 32824394
Drug: Exercise treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise treatment group
Study: 36215327
Drug: Digital home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital home exercise program (12-week duration, four exercises daily)
Study: 34297066
Drug: Placebo (lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactated Ringer's solution)
Study: 32354590
Drug: Subcutaneous mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous mepivacaine
Study: 32964203
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg/d)
Study: 35373862
Drug: DHA fish
Normalized name: Fish Oil 1000 MG Oral Capsule, Liquid Filled [OMEGA-3 EPA & DHA FISH OIL CONCENTRATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA fish oil supplement (1491 mg DHA + 351 mg eicosapentaenoic acid per day)
Study: 32880050
Drug: Contrast water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast water therapy (CWT, alternately 10 °C and 38 °C)
Study: 34751757
Drug: Early surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early surgical treatment